# Harmony Biosciences Schedules Q2 2025 Earnings and Confirms Fragile X Phase 3 Readout Timeline

> news · REPORTED · 2025-07-22

On July 22, 2025, Harmony Biosciences confirmed it will report Q2 2025 financial results on August 5, 2025, and reaffirmed that topline data from the pivotal Phase 3 RECONNECT study of ZYN002 (cannabidiol) in Fragile X syndrome is on track for Q3 2025, a potential first-ever approved treatment for this rare neurodevelopmental condition affecting approximately 80,000 U.S. patients.

About Harmony Biosciences Holdings, Inc.: Harmony Biosciences (Nasdaq: HRMY) is a rare neurological disease pharmaceutical company headquartered in Plymouth Meeting, Pennsylvania, known for WAKIX (pitolisant) for narcolepsy and a neuroscience pipeline spanning Fragile X syndrome, epilepsy, and sleep-wake disorders.

- Company: Harmony Biosciences Holdings, Inc.
- Sector: therapeutics
- Primary source: https://www.businesswire.com/news/home/20250722796867/en/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.